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Peptide and Lipopeptide Self‐assembly {#psc2954-sec-0001}
=====================================

The self‐assembly of peptides in solution is driven by a combination of hydrogen bonding, electrostatic and other (e.g. π‐stacking) interactions that also contribute to the self‐assembly of lipopeptides [1](#psc2954-bib-0001){ref-type="ref"}. However, in the latter class of system, hydrophobic interactions are important. The self‐assembly of peptides and lipopeptides can be influenced by many variables including concentration, pH, ionic strength of solution or temperature [2](#psc2954-bib-0002){ref-type="ref"}.

Many self‐assembling molecules are amphiphilic, meaning they have both hydrophobic and hydrophilic character. They generally self‐assemble above a critical concentration, known as the critical aggregation concentration (CAC). Amphiphilic molecules such as lipids, peptides and proteins serve as building blocks for the construction of functional assemblies *in vivo*, e.g. the cytoskeleton and extracellular matrix. Lipids are one of the simplest amphiphilic structures and are composed of a hydrophilic polar head group and a hydrophobic tail. Peptides and proteins, however, are distinct in the way in which amphiphilicity is displayed because when folded, they can display regions that are either hydrophobic or hydrophilic. An example of this is an *α*‐helix, as it could contain a section of hydrophobic residues along one face and a hydrophilic section of residues on the opposite face. For *β*‐sheet structures, the peptide chain can be composed of alternating hydrophilic and hydrophobic residues, so that the side chains of the residues are displayed on opposite faces of the sheet.

In aqueous environments, amphiphilic molecules associate through non‐covalent interactions to form ordered assemblies of different sizes, from nanometres to microns [3](#psc2954-bib-0003){ref-type="ref"}. These self‐assembled structures include spherical and worm‐like micelles, vesicles, fibrils and nanotubes (Figure [1](#psc2954-fig-0001){ref-type="fig"}). Micelles consist of a hydrophobic inner core surrounded by a hydrophilic outer shell that is exposed to water, and they can be spheres, discs or worm‐like structures [4](#psc2954-bib-0004){ref-type="ref"}. Micelles form spontaneously when the concentration is above a critical micelle concentration \[CMC\] and temperature [5](#psc2954-bib-0005){ref-type="ref"}. The CMC is a subcategory of CAC, which is a more general term for the aggregation into many different structures.

![Molecular interactions and possible self‐assembled structures of typical lipopeptides.](PSC-23-82-g001){#psc2954-fig-0001}

Amphiphiles with an intermediate level of hydrophobicity can assemble into bilayer vesicles. Vesicles are spherical, hollow, lamellar structures with an aqueous core. The hydrophobic moieties form the inner section of the bilayer, and the hydrophilic parts are exposed to the aqueous environment [6](#psc2954-bib-0006){ref-type="ref"}.

Self‐assembling peptides are peptides that undergo spontaneous assembly into ordered nanostructures. This is observed depending on the hydrophilic/lipophilic balance of the molecules, as well as the interactions between the peptide units [7](#psc2954-bib-0007){ref-type="ref"}. In one case of self‐assembling peptides, hydrogen bonding between backbones plays an important role by forcing the peptide monomers to pack longitudinally into *β*‐sheets. The inter‐sheet interactions between the side chains of the peptides regulate lateral packing, and the stronger these interactions, the better the lateral packing [8](#psc2954-bib-0008){ref-type="ref"}. A further type of self‐assembling peptide forms coiled coil structures, formed from aggregated *α*‐helices [9](#psc2954-bib-0009){ref-type="ref"}.

Among all organic building blocks, peptides are very promising platforms because of their ease of synthesis, chemical diversity and their similar biological properties to proteins. In addition to this, peptides are very useful components in creating self‐assembled nanostructures because of their biocompatibility, biodegradability and biofunctionality [10](#psc2954-bib-0010){ref-type="ref"}.

The number, type and sequence of amino acids determines the self‐assembly of peptides, and depending on the amino acid sequence, the peptide can form a variety of different structures. As a result of this, peptides provide a unique platform for the design of nanomaterials with controllable structural features. Self‐assembled peptide nanostructures have demonstrated potential use for many biomedical applications such as drug delivery, tissue engineering and antimicrobial agents, to name a few, and several of these applications are discussed in detail in the following.

Peptide Amphiphiles {#psc2954-sec-0002}
===================

Peptide amphiphiles (PAs) may comprise sequences of hydrophobic and hydrophilic peptides or hydrophilic peptides attached to lipid chains. The class of PA termed lipopeptide consists of one or more lipid chains attached to hydrophilic peptide sequences containing charged residues [2](#psc2954-bib-0002){ref-type="ref"}, [7](#psc2954-bib-0007){ref-type="ref"}. They are a class of molecules that combine the structural features of amphiphilic surfactants with the functions of bioactive peptides, and they are known to assemble into a variety of nanostructures [11](#psc2954-bib-0011){ref-type="ref"}, [12](#psc2954-bib-0012){ref-type="ref"}. It is proposed that PAs designed to form bioactive fibrils should be composed of four key structural features (Figure [2](#psc2954-fig-0002){ref-type="fig"}): A hydrophobic domain that is typically an alkyl chain attached to a peptide sequence, which favours intermolecular hydrogen bonding. Then there is a charged amino acid domain that enhances solubility in water. The final structural feature that makes up a peptide amphiphile is a bio‐derived or bio‐inspired epitope that allows interaction with cells or proteins [13](#psc2954-bib-0013){ref-type="ref"}.

![The four domains in a PA molecule required for self‐assembly into *β*‐sheet fibrils with a coating of bioactive epitopes [11](#psc2954-bib-0011){ref-type="ref"}.](PSC-23-82-g002){#psc2954-fig-0002}

Molecules that contain both polar and non‐polar elements often undergo self‐assembly, which allows the hydrophilic moieties to be exposed to the aqueous environment and the hydrophobic moieties to be shielded from the aqueous media. There is normally a distinct relationship between the amphiphilic character of a peptide and its function [12](#psc2954-bib-0012){ref-type="ref"}. For example, amphiphilic peptides fold into helices or sheets to allow the non‐polar residues to interact with the lipid chains in the interior of the cell membrane and to allow the polar residues to be exposed to the aqueous environment. This self‐assembly allows the peptide molecules to optimise their interaction with the surroundings.

Peptide amphiphiles have great potential in biomedical applications [1](#psc2954-bib-0001){ref-type="ref"}, [11](#psc2954-bib-0011){ref-type="ref"}, [13](#psc2954-bib-0013){ref-type="ref"}, [14](#psc2954-bib-0014){ref-type="ref"}, [15](#psc2954-bib-0015){ref-type="ref"}, [16](#psc2954-bib-0016){ref-type="ref"}, [17](#psc2954-bib-0017){ref-type="ref"}, [18](#psc2954-bib-0018){ref-type="ref"} and can be utilised to act as therapeutic agents to treat diseases by delivering drugs. They can then be metabolised into lipids and amino acids, which are then easily cleared by the kidneys [19](#psc2954-bib-0019){ref-type="ref"}. In therapeutic applications, the hydrophobic tail assists transport across the cell membrane, and the peptide epitope can then be used to target a specific cell via a ligand‐receptor complex [20](#psc2954-bib-0020){ref-type="ref"}.

Lipopeptides are able to form supramolecular nanostructures such as fibrils, micelles and vesicles. Lipopeptide biosurfactants (surfactants of biological origin) are produced by a wide variety of bacteria, fungi and yeast [7](#psc2954-bib-0007){ref-type="ref"}, [21](#psc2954-bib-0021){ref-type="ref"}. They are surface active compounds that have the ability to decrease the surface and interfacial tension, allowing them to disrupt biological activity as part of the organism\'s host defence mechanism [21](#psc2954-bib-0021){ref-type="ref"}.

Applications of Self‐assembled PAs and Lipopeptides {#psc2954-sec-0003}
===================================================

Lipopeptides have a wide range of applications such as use as antimicrobial agents and in immune disease therapies, cosmeceuticals and also fungicides, all of which are explained in more detail in the succeeding sections.

Biosurfactants with Antimicrobial and Antifungal Applications {#psc2954-sec-0004}
-------------------------------------------------------------

There are many types of lipopeptides; among the most popular are the classes of surfactins, iturins and fengycins, which are produced by the *Bacillus subtilis* family [21](#psc2954-bib-0021){ref-type="ref"}, [22](#psc2954-bib-0022){ref-type="ref"}, [23](#psc2954-bib-0023){ref-type="ref"}. *B. subtilis* strains produce a wide range of lipopeptides that are potent biosurfactants and have specific antimicrobial and antiviral activities [21](#psc2954-bib-0021){ref-type="ref"}. The fact that surfactins are biosurfactants means that they have diverse functional properties such as low toxicity, biodegradability and a higher tolerance towards variation of temperature and pH [21](#psc2954-bib-0021){ref-type="ref"}. Iturins are pore‐forming lipopeptides with antifungal activity, and this is dependent on the interaction with the cytoplasmic membrane of the target cells [21](#psc2954-bib-0021){ref-type="ref"}, [22](#psc2954-bib-0022){ref-type="ref"}, [24](#psc2954-bib-0024){ref-type="ref"}. Finally, fengycins are another class of biosurfactant with antifungal properties [23](#psc2954-bib-0023){ref-type="ref"}, [24](#psc2954-bib-0024){ref-type="ref"}.

Toll‐like Receptor Agonists {#psc2954-sec-0005}
---------------------------

Lipopeptides, such as those incorporating the CSK~4~ peptide motif and one, two or three palmitoyl (hexadecyl) chains [25](#psc2954-bib-0025){ref-type="ref"}, can also act as toll‐like receptor (TLR) agonists, which have important applications in the treatment of disease. TLRs are transmembrane proteins that are very important in the immune system and as a result are therapeutic targets to treat disease.

These receptor agonists respond to invading pathogens by recognising specific pathogen‐associated microbial patterns (PAMPs) or danger‐associated molecular patterns (DAMPs), which are primarily produced by microbial pathogens [26](#psc2954-bib-0026){ref-type="ref"}. PAMPs can contain a variety of different components including lipopolysaccharide, peptidoglycan, lipopeptide and bacterial DNA. DAMPs can be intracellular proteins or proteins from the extracellular matrix [27](#psc2954-bib-0027){ref-type="ref"}, [28](#psc2954-bib-0028){ref-type="ref"}.

Toll‐like receptors have a common structure being type‐1 transmembrane proteins. This includes having an extracellular domain formed from leucine‐rich repeats (LRRs) and a cytoplasmic tail containing an area known as the TLR domain. X‐ray crystallography reveals that the LRR domain has a horseshoe‐like shape [29](#psc2954-bib-0029){ref-type="ref"}, traversing the membrane. Currently, 10 TLRs have been found in humans, each with a different role and target [30](#psc2954-bib-0030){ref-type="ref"}.

Toll‐like receptor agonists are compounds that stimulate these receptors to modulate the interaction with one of the PAMPs/DAMPs described earlier. The development of synthetic or natural agonists is an interesting avenue of research to treat a multitude of conditions that includes, but is not limited to; advanced melanoma [31](#psc2954-bib-0031){ref-type="ref"}, alcoholic chronic liver disease [32](#psc2954-bib-0032){ref-type="ref"}, asthma [33](#psc2954-bib-0033){ref-type="ref"}, neuropathic pain [34](#psc2954-bib-0034){ref-type="ref"} and restenosis (re‐narrowing of the blood vessels) [35](#psc2954-bib-0035){ref-type="ref"}.

Skincare {#psc2954-sec-0006}
--------

Peptide amphiphiles are employed in skincare products with the claimed ability to help stimulate collagen production. A commercially available lipopeptide with the trade name Matrixyl™ \[C~16~‐Lys‐Thr‐Thr‐Lys‐Ser (KTTKS)\] has been used in anti‐wrinkle creams. This lipopeptide has been shown to self‐assemble into a *β*‐sheet tape‐like superstructure (Figure [3](#psc2954-fig-0003){ref-type="fig"}). Small‐angle X‐ray scattering further established a bilayer structure with a spacing of 5.3 nm [36](#psc2954-bib-0036){ref-type="ref"}.

![Confocal microscopy image of Matrixyl™ fibre superstructure. (Labelled with the dye rhodamine B, 0.0014 w% Matrixyl™ in water) [36](#psc2954-bib-0036){ref-type="ref"}.](PSC-23-82-g003){#psc2954-fig-0003}

The mechanism for this stimulation of collagen expression is not fully understood, but it has been reported that the KTTKS polypeptide increases the skin\'s extracellular matrix (ECM) production [37](#psc2954-bib-0037){ref-type="ref"}, [38](#psc2954-bib-0038){ref-type="ref"}. ECM is the outer region of a cell that supports the cells and those around it. The conjugation of the KTTKS peptide motif to a palmitoyl (C~16~) chain has been shown to enhance skin permeability, and the self‐assembled structure (Figure [3](#psc2954-fig-0003){ref-type="fig"}) presents a peptide‐rich surface on the nanotapes, these features contributing towards increased collagen production making it a highly sought after skincare additive. This lipopeptide\'s collagen‐stimulating activity occurs even at low concentration, close to its [37](#psc2954-bib-0037){ref-type="ref"}. Other lipopeptides, such as C~16~‐GHK or C~16~‐KT, also have been reported to have collagen‐stimulating effects, and their self‐assembly has been examined [39](#psc2954-bib-0039){ref-type="ref"}.

Tissue Scaffolds {#psc2954-sec-0007}
----------------

Various groups have looked into the use of PAs and lipopeptides as scaffolds for the production of tissue or for other applications in regenerative medicine. In one study, the linear RGD amino acid sequence was conjugated with dialkyl chains. This scaffold allowed for spreading of melanoma and endothelial cells when it was carboxyl‐coupled, but spreading was not seen with amino‐coupled dialkyl chains [40](#psc2954-bib-0040){ref-type="ref"}. Another group managed to encapsulate cells within nanofibrils made up of PAs with the Ile‐Lys‐Val‐Ala‐Val (IKVAV) peptide group (Figure [4](#psc2954-fig-0004){ref-type="fig"}). These PAs were shown to be effective at treating spinal cord injuries in mice. This was due to the nanofibrils inhibiting scar formation, which helped lessen the injury [41](#psc2954-bib-0041){ref-type="ref"}. This is a fascinating and broad topic that has been reviewed in much detail elsewhere by the Stupp group and is therefore outside the scope of the present review [42](#psc2954-bib-0042){ref-type="ref"}, [43](#psc2954-bib-0043){ref-type="ref"}, [44](#psc2954-bib-0044){ref-type="ref"}, [45](#psc2954-bib-0045){ref-type="ref"}, [46](#psc2954-bib-0046){ref-type="ref"}, [47](#psc2954-bib-0047){ref-type="ref"}.

![Self‐assembly of IKVAV functionalized PAs into fibrils [42](#psc2954-bib-0042){ref-type="ref"}.](PSC-23-82-g004){#psc2954-fig-0004}

Antimicrobial Materials {#psc2954-sec-0008}
-----------------------

There are a great number of studies on peptides with antimicrobial properties [48](#psc2954-bib-0048){ref-type="ref"}, [49](#psc2954-bib-0049){ref-type="ref"}, [50](#psc2954-bib-0050){ref-type="ref"}. A common feature for antimicrobial activity is the presence of cationic residues such as lysine or more especially arginine as these can interact with cell walls. Lipidation of peptides has been shown to improve the uptake of the peptide into the cell [51](#psc2954-bib-0051){ref-type="ref"}. This was investigated with a range of Gram‐negative/positive bacteria and two fungal strains. Uptake into the cell wall and then subsequent disruption of the cell membrane was found out to be the mode of action, which caused bacterial leakage and cell death [51](#psc2954-bib-0051){ref-type="ref"}. A peptide containing a trans‐activating transcriptional activator (TAT) sequence along with an amphiphilic Gly--Arg sequence conjugated to cholesterol was also found to be an effective antimicrobial agent [52](#psc2954-bib-0052){ref-type="ref"}. This peptide was shown to work by the same process of incorporation into the cell membrane followed by its disruption. The paper also showed that the PA can also be transported across the blood--brain barrier [52](#psc2954-bib-0052){ref-type="ref"}. One of the most well‐known lipopeptides used in treating infections is daptomycin (Figure [5](#psc2954-fig-0005){ref-type="fig"}) [53](#psc2954-bib-0053){ref-type="ref"}.

![Daptomycin chemical structure, redrawn from [53](#psc2954-bib-0053){ref-type="ref"}.](PSC-23-82-g005){#psc2954-fig-0005}

Daptomycin is able to combat systemic and life‐threatening infections and is trademarked under the name Cubicin. It comprises a cyclic peptide group joined by an amide linkage to a lipid chain. The mechanism by which daptomycin acts on bacteria has been carefully examined [54](#psc2954-bib-0054){ref-type="ref"}. It works by insertion of the lipid chain into the cell wall. Daptomycin molecules then aggregate, deforming the curvature of the membrane, causing holes to form and leading to the leakage of ions from the cell. This then causes a serious depolarization resulting in the inhibition of various synthesis processes including those of DNA, protein and RNA. This combines to cause cell death. The self‐assembly of daptomycin was studied outside of the cell and it was shown to aggregate into micelles [53](#psc2954-bib-0053){ref-type="ref"}. This aggregation process may be correlated to its excellent antimicrobial activity. A recent review on the self‐assembly of lipopeptides including therapeutic lipopeptides is available [7](#psc2954-bib-0007){ref-type="ref"}.

Drug Delivery {#psc2954-sec-0009}
-------------

Lipopeptides are interesting vehicles for drug delivery with several modes of activity. In one, the self‐assembled structure of the PA is exploited, i.e. the hydrophobic area inside a micelle or bilayer structure is used to house a hydrophobic drug molecule. It is important to distinguish between PAs with inherent therapeutic potential and those that are merely vehicles or devices. In the former case, many types of bioactive peptides have been lipidated to create active pharmaceutical ingredients (APIs) (e.g. Table [1](#psc2954-tbl-0001){ref-type="table-wrap"}). In the latter case, the self‐assembled structure allows for the transport of the drug in highly aqueous environments to the target cells. An example of this is a TAT~48--60~ fragment conjugated with one, two or four attached octanoic acid groups [55](#psc2954-bib-0055){ref-type="ref"}. These TAT PAs form β‐sheet structures. It was shown that the PA with four octanoic acid groups could encapsulate and retain the hydrophobic drug paclitaxel. This was deemed to be due to the high hydrophobicity of the octanoic acid groups. This encapsulation was highly efficient (6.8±0.4%), compared with previous nanoscale delivery vehicles for which encapsulation rarely exceeds 5%, making it a favoured drug delivery system [55](#psc2954-bib-0055){ref-type="ref"}. Another strategy to create PAs for drug delivery is the lipidation of receptor‐specific peptide head groups. The peptide head groups bind selectively to the receptor, while the lipid group allows the PA to cross cell membranes and also increases bioactivity through reducing metabolic degradation [56](#psc2954-bib-0056){ref-type="ref"}, [57](#psc2954-bib-0057){ref-type="ref"}. A good example of this is an amphiliphic lipopeptide comprising a palmitoyl (C~16~) ester linked to Ala‐Gly‐Phe‐Leu‐Arg peptide motif, incorporating the anticancer drug Dalargin (Ala--Gly--Phe--Leu--Arg), which formed into nanofibres [58](#psc2954-bib-0058){ref-type="ref"}.These fibres have high circulation times and also more importantly can cross the BBB. This allows the normally hydrophobic cancer drug to potentially be used to treat cancers in the brain, overcoming its low circulation and high hydrophobicity [58](#psc2954-bib-0058){ref-type="ref"}.

###### 

Peptide therapeutics on the market

  Trade name        Peptide        Company        Molecular properties                                                                                                                                      Related reference
  ----------------- -------------- -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
  Copaxone          Glatiramer     Teva           Four amino acids ([l]{.smallcaps}‐glutamic acid, [l]{.smallcaps}‐alanine, [l]{.smallcaps}‐lysine and [l]{.smallcaps}‐tyrosine) in a defined molar ratio   [105](#psc2954-bib-0105){ref-type="ref"}, [106](#psc2954-bib-0106){ref-type="ref"}
  Lupron            Leuprolide     Abbott         Synthetic nonapeptide analogue of naturally occurring gonadotropin‐releasing hormone (GnRH or LH‐RH)                                                      [107](#psc2954-bib-0107){ref-type="ref"}, [108](#psc2954-bib-0108){ref-type="ref"}
  Vicoza            Liraglutide    Novo           97% homologous to native human GLP‐1 (7--37) by substituting arginine for lysine at position 34 and addition of a fatty acid chain                        [109](#psc2954-bib-0109){ref-type="ref"}
  Zoladex           Goserelin      AZ             Natural LHRH/GnRH decapeptide with two substitutions to inhibit rapid degradation.                                                                        [110](#psc2954-bib-0110){ref-type="ref"}, [111](#psc2954-bib-0111){ref-type="ref"}
  Sandostatin       Octreotide     Novartis       Longer acting synthetic octapeptide analogue of naturally occurring somatostatin                                                                          [112](#psc2954-bib-0112){ref-type="ref"}, [113](#psc2954-bib-0113){ref-type="ref"}
  Forteo            Teriparatide   Lilly/Amylin   Recombinant form of parathyroid hormone consisting of the first (N‐terminus) 34 amino acids, which is the bioactive portion of the hormone                [114](#psc2954-bib-0114){ref-type="ref"}, [115](#psc2954-bib-0115){ref-type="ref"}
  Byetta            Exenatide      Lilly/Amylin   Synthetic version of exendin‐4, a hormone found in the saliva of the Gila monster                                                                         [116](#psc2954-bib-0116){ref-type="ref"}, [117](#psc2954-bib-0117){ref-type="ref"}
  Cubicin           Daptomycin     Cubist         Cyclic lipopeptide, consisting of 13 amino acids, 10 of which are arranged in a cyclic fashion and three on an exocyclic tail                             [118](#psc2954-bib-0118){ref-type="ref"}, [119](#psc2954-bib-0119){ref-type="ref"}
  Integrilin        Eptifibatide   Merck          Cyclic heptapeptide composed with S--S bridge, two unnatural building blocks and amide                                                                    [120](#psc2954-bib-0120){ref-type="ref"}, [121](#psc2954-bib-0121){ref-type="ref"}
  Angiomax/angiox   Bivalirudin    Medicines      20‐amino acid polypeptide                                                                                                                                 [122](#psc2954-bib-0122){ref-type="ref"}, [123](#psc2954-bib-0123){ref-type="ref"}
  Fortical          Calcitonin     Upsher‐Smith   32‐amino acid polypeptide                                                                                                                                 [124](#psc2954-bib-0124){ref-type="ref"}, [125](#psc2954-bib-0125){ref-type="ref"}, [126](#psc2954-bib-0126){ref-type="ref"}
  Somatuline        Lanreotide     Ipsen          Cyclic peptide that is a long‐acting analogue of somatostatin.                                                                                            [127](#psc2954-bib-0127){ref-type="ref"}, [128](#psc2954-bib-0128){ref-type="ref"}

Biomaterial Templating {#psc2954-sec-0010}
----------------------

The various structures formed by PAs and lipopeptides have been exploited to template distinct inorganic materials (salts, metal oxides and metals), sometimes allowing for unique structures to be formed. PA nanostructures have the potential, for example, to be used to template the bone mineral hydroxyapatite, which is the body\'s primary storage depot for calcium and phosphorus in bones [59](#psc2954-bib-0059){ref-type="ref"}, [60](#psc2954-bib-0060){ref-type="ref"}. A further avenue of interest is the incorporation of other metals, such as titanium, with mineralizing PAs to form hybrid bone implants. In one example, a titanium alloy foam was mixed with different PAs solutions and then further allowed to mineralise calcium phosphate. This was shown (Figure [6](#psc2954-fig-0006){ref-type="fig"}) to form new, immature bone adjacent and inside the hybrid, after 4 weeks [61](#psc2954-bib-0061){ref-type="ref"}. This field of research is highly active and may, in the future, allow for treatment of bone diseases such as hydroxyapatite deposition disease or dystrophic calcification, among others.

![Time‐sequence photographs of a mineralising 3D PA matrix [61](#psc2954-bib-0061){ref-type="ref"}.](PSC-23-82-g006){#psc2954-fig-0006}

Peptide Hormones {#psc2954-sec-0011}
================

Peptide hormones are hormones made up of amino acid chains that primarily have an effect on the endocrine system. Based on the building units, hormones can be classified as either amino acid‐based or steroid‐based systems. The presence of amino acids in peptide hormones allows them to act on the surface of target cells via secondary messengers. This differs from steroid hormones that are lipid soluble, and so can move through the plasma membranes of target cells and act within the nuclei [62](#psc2954-bib-0062){ref-type="ref"}.

The endocrine system is composed of many different glands, and it can be divided into two categories: classical and non‐classical. In the endocrine system, hormones are secreted into the circulatory system where they are distributed throughout the body, regulating bodily functions. The classical endocrine glands include the pituitary gland, pancreas, thyroid gland, adrenal cortex and medulla. The primary function of these glands is to manufacture specific hormones. Non‐classical endocrine glands include the heart, hypothalamus, kidneys, liver and the gastrointestinal tract. Many of the classical hormones are controlled by the hypothalamus and pituitary, which can also be classified as being an extension of the nervous system [63](#psc2954-bib-0063){ref-type="ref"}.

Gut--Brain Interactions {#psc2954-sec-0012}
=======================

Gut--brain interactions are increasingly recognised as playing an important role in determining overall food intake [63](#psc2954-bib-0063){ref-type="ref"}. Many peptides are synthesised and released from the gastrointestinal tract, and it has been shown that they physiologically influence eating behaviour via gut--brain signalling [64](#psc2954-bib-0064){ref-type="ref"}. Ghrelin is an appetite‐stimulating peptide produced in the stomach, which acts as a meal initiator. This differs from peptide YY, pancreatic polypeptide (PP), glucagon‐like peptide‐1 (GLP‐1), oxyntomodulin (OXM) and cholecystokinin (CCK), which are all derived from the intestine and pancreas and have been shown to produce satiety signals. From this, it has been suggested that gut hormones can be manipulated to regulate energy balance, and as a result, gut hormone‐based therapies could be a possible treatment for obesity (Figure [7](#psc2954-fig-0007){ref-type="fig"}) [65](#psc2954-bib-0065){ref-type="ref"}, [66](#psc2954-bib-0066){ref-type="ref"}.

![Interactions of gut and endocrine hormones with the brain and how they affect food intake [66](#psc2954-bib-0066){ref-type="ref"}.](PSC-23-82-g007){#psc2954-fig-0007}

Peptide Hormones Involved with the Gastrointestinal Tract and Feeding {#psc2954-sec-0013}
=====================================================================

Leptin {#psc2954-sec-0014}
------

Leptin is a [hormone](https://en.wikipedia.org/wiki/Hormone) made by [adipose cells](https://en.wikipedia.org/wiki/Adipose_cells) that affects many biological mechanisms including reproduction, the immune and inflammatory response, haematopoiesis, angiogenesis, bone formation and wound healing. More interestingly, however, leptin helps to regulate [energy balance](https://en.wikipedia.org/wiki/Energy_homeostasis) by inhibiting hunger. This occurs via a feedback mechanism in which signals are sent to key regulatory centres in the brain to inhibit food intake [67](#psc2954-bib-0067){ref-type="ref"}.

After leptin is released by the adipose tissue into the bloodstream, it crosses the BBB and binds to the hypothalamic leptin receptors. This affects the activity of many hypothalamic neurones and the expression of various orexigenic (appetite stimulating) and anorexigenic neuropeptides. Orexigenic peptides include neuropeptide Y (NPY), and anorexigenic peptides include pro‐opiomelanocortin. It has been suggested that the interaction with both types of these neuropeptides underpins the mechanism of action of leptin in the hypothalamus to inhibit hunger [67](#psc2954-bib-0067){ref-type="ref"}.

Ghrelin {#psc2954-sec-0015}
-------

Ghrelin is a 28‐amino acid peptide with an octanoylated serine residue at position 3 [68](#psc2954-bib-0068){ref-type="ref"} and is produced and secreted by cells within the oxyntic glands of the stomach [65](#psc2954-bib-0065){ref-type="ref"}. Peripheral administration of ghrelin has been shown to stimulate food intake and decrease fat utilisation. This means it is involved in energy homeostasis, and it is the serine residue that appears to give ghrelin these effects [68](#psc2954-bib-0068){ref-type="ref"}. What makes ghrelin unique is its function to increase food intake rather than decrease it, and as a result, it is a very important component of weight control. Evidence of this was shown when a study was carried out on mice that were lacking in ghrelin. The results showed that they were resistant to diet‐induced obesity when fed a high‐fat diet due to them eating less, and therefore utilising more stored fat as an energy source [66](#psc2954-bib-0066){ref-type="ref"}.

Cholecystokinin {#psc2954-sec-0016}
---------------

Cholecystokinin is an endogenous gut hormone mainly found in the duodenum and jejunum, which exists in several molecular forms with differing numbers of amino acids. Examples include CCK‐8 and CCK‐54 (the number indicates the number of amino acid residues). CCK is known to act as a postprandial satiety signal, and it acts via two receptors: CCK~1~ and CCK~2~. The CCK~1~ receptor is more important in appetite control [68](#psc2954-bib-0068){ref-type="ref"}. The receptors are located on the peripheral vagal afferent terminals, which transmit signals to the part of the brain stem that is associated with appetite, such as the nucleus of the solitary tract [66](#psc2954-bib-0066){ref-type="ref"}.

Oxyntomodulin {#psc2954-sec-0017}
-------------

Oxyntomodulin is a 37‐amino acid peptide expressed in the central nervous system and the L cells of the intestine and pancreas [69](#psc2954-bib-0069){ref-type="ref"}. OXM seems to mediate its effects via the GLP‐1 receptor as shown in experiments carried out on rat parietal cells [70](#psc2954-bib-0070){ref-type="ref"}. This has been proven since its anorectic actions are blocked when the GLP‐1 antagonist was administered [71](#psc2954-bib-0071){ref-type="ref"}. Intravenous administration of OXM in humans inhibits gastric emptying and gastric acid secretion, which leads to a feeling of satiety [72](#psc2954-bib-0072){ref-type="ref"}. This feeling of satiety can cause a reduction in both food intake and overall body weight, and this is brought about by the suppression of ghrelin.

Glucagon‐like Peptide‐1 {#psc2954-sec-0018}
-----------------------

Glucagon‐like peptide‐1 is a 30‐amino acid gut‐derived incretin peptide hormone [73](#psc2954-bib-0073){ref-type="ref"} meaning that it stimulates insulin secretion in response to eating, and as a result, it suppresses glucagon secretion. In addition to this, GLP‐1 inhibits gastric emptying and also reduces appetite and food intake [74](#psc2954-bib-0074){ref-type="ref"}. GLP‐1 is produced in the intestinal epithelial endocrine L cells in the distal small bowel and colon by differential processing of proglucagon [73](#psc2954-bib-0073){ref-type="ref"}, [74](#psc2954-bib-0074){ref-type="ref"}. Proglucagon is the gene that is expressed in the L cells and is regulated in the gut and brain [74](#psc2954-bib-0074){ref-type="ref"}. Within minutes of food intake, the plasma levels of GLP‐1 rise rapidly. GLP‐1 exists in two circulating molecular forms: GLP‐1(7--37) and GLP‐1(7--36) amide, and it is GLP‐1(7--36) amide that represents the majority of circulating active GLP‐1 in human plasma. Both forms of GLP‐1 are rapidly metabolised and inactivated by the enzyme dipeptidyl peptidase‐4 (DPP‐4) to GLP‐1(9--37) or GLP‐1(9--36) amide following the release from gut L cells [75](#psc2954-bib-0075){ref-type="ref"}. This widely expressed enzyme cleaves both forms of GLP‐1 at the position 2 alanine of the N‐terminal to make them inactive. The expression of DPP‐4 in the gut and vascular endothelium explains the short half‐life of GLP‐1 of just several minutes, because the majority of immunoreactive GLP‐1 entering the portal venous circulation has already been inactivated by N‐terminal cleavage [76](#psc2954-bib-0076){ref-type="ref"}.

Pancreatic Polypeptide {#psc2954-sec-0019}
----------------------

Pancreatic polypeptide is a 36‐amino acid peptide that belongs to a family that includes NPY and peptide YY (PYY), and all of these peptides are members of the PP‐fold peptide family. The PP‐fold family binds to receptors Y~1~--Y~6~, but PP in particular has the highest affinity for the Y~4~ and Y~5~ receptors [68](#psc2954-bib-0068){ref-type="ref"}. PP is similar to GLP‐1 in that it is released into the circulation after the ingestion of food. However, it differs in that it is produced in the endocrine F cells, which are located in the periphery of the pancreatic islets [77](#psc2954-bib-0077){ref-type="ref"}, [78](#psc2954-bib-0078){ref-type="ref"}. PP is responsible for a number of regulatory actions, such as the inhibition of pancreatic exocrine secretion, and the modulation of gastric acid secretion, and gastric emptying [79](#psc2954-bib-0079){ref-type="ref"}, [80](#psc2954-bib-0080){ref-type="ref"}. The amount of PP released is affected by the digestive state, i.e. release is very low in the fasted state but is significantly increased throughout all phases of digestion. In addition to this, PP is affected by a decrease in blood glucose levels and insulin‐induced hypoglycaemia, both being stimuli for PP secretion in the brain. As a result of this, it is thought that PP could potentially play a significant role in the regulation of feeding behaviour to control energy homeostasis [77](#psc2954-bib-0077){ref-type="ref"}.

Peptide YY {#psc2954-sec-0020}
----------

Peptide YY is a gut hormone that belongs to the PP family, along with PP and NPY, all of which are given the term PP‐fold family. The PP‐fold motif is found throughout this family and relates to the 3D structure. The PP‐fold is formed through the incorporation of certain residues, which are predominately Pro2, Pro5, Pro8, Gly9, Tyr20 and Tyr27. The PP‐fold has been found to protect the peptide against enzymatic attack as well as producing a hydrophobic pocket that is inherently overall energy‐reducing. In addition to containing the PP‐fold motif, PYY and its derivative PYY~3--36~ also have a high C‐terminal *α*‐helix content, which has also been suggested to be extremely important for the structural integrity of PYY. The sequence of the 36‐amino acid peptide, PYY, is Tyr--Pro--Ala--Lys--Pro--Glu--Ala--Pro--Gly--Glu--Asp--Ala--Ser--Pro--Glu--Glu--Leu--Ser--Arg--Tyr--Tyr--Ala--Ser--Leu--Arg--His--Tyr--Leu--Asn--Leu--Val--Thr--Arg--Gln--Arg--Tyr--NH~2~ [81](#psc2954-bib-0081){ref-type="ref"}.

Temperature‐dependent circular dichroism (CD) studies have been carried out on human PYY to characterise its secondary structure. The results indicated an *α*‐helical structure due to a maximum near 190 nm and two minima near 208 and 222 nm. A minimum near 200 nm was also observed, which corresponds to a random‐coil structure (Figure [8](#psc2954-fig-0008){ref-type="fig"}) [82](#psc2954-bib-0082){ref-type="ref"}.

![Temperature dependant CD spectra of human PYY in 20 mM acetate buffer at pH 4.6 [82](#psc2954-bib-0082){ref-type="ref"}.](PSC-23-82-g008){#psc2954-fig-0008}

The PP‐fold PP family all consists of a signal peptide, followed by a 36‐amino acid active peptide and a carboxyl‐terminal [83](#psc2954-bib-0083){ref-type="ref"}, and they mediate their effects through the NPY receptors Y~1~, Y~2~, Y~4~ and Y~5~ [84](#psc2954-bib-0084){ref-type="ref"}. The Y‐receptors belong to the G protein‐coupled receptor family, and they mediate a wide variety of physiological effects such as regulation of blood pressure, anxiety, memory retention, hormone release and food intake.

Peptide YY is released by the L cells of the gastrointestinal tract following food intake, and there are two main endogenous forms: PYY~1--36~ and PYY~3--36~. PYY~1--36~ is rapidly processed by the enzyme DPP‐4 to the 34‐amino acid peptide PYY~3--36~ [85](#psc2954-bib-0085){ref-type="ref"}. DPP‐4 hydrolyses PYY and removes the first two amino acids, tyrosine and proline, at the N‐terminal, which changes the receptor selectivity. As a result of this, PYY~3--36~ has a high selectivity for the Y~2~‐receptor, compared with PYY~1--36~, which has selectivity for the Y~1~, Y~2~ and Y~5~ receptors. It is thought that the Y~1~ receptor requires both the C‐terminus and N‐terminus for recognition, binding and then subsequent activation. The Y~2~ receptor is thought to have a smaller receptor site and also only requires the C‐terminus for recognition (Figure [9](#psc2954-fig-0009){ref-type="fig"}).

![Binding sites for Y1 and Y2 with hPYY + hPYY~(3--36)~ [86](#psc2954-bib-0086){ref-type="ref"}.](PSC-23-82-g009){#psc2954-fig-0009}

This could explain the reduced affinity for PYY~3--36~ on any Y receptor other than Y~2~ [86](#psc2954-bib-0086){ref-type="ref"}. Other studies replacing the amide bonds with ester bonds also confirm that the end section is important in binding and activation [87](#psc2954-bib-0087){ref-type="ref"}. The Y~2~ receptors are located in the hippocampus, sympathetic and parasympathetic nerve fibres, intestines and certain blood vessels and have been implicated in regulating food intake and gastric emptying [88](#psc2954-bib-0088){ref-type="ref"}. As a result of this, the Y~2~ receptor is considered a target for the treatment of obesity and type 2 diabetes.

Neuropeptide Y {#psc2954-sec-0021}
--------------

Neuropeptide Y is also a 36‐amino acid peptide that has a very similar sequence homology to PYY and PP. NPY, however, differs from the other two peptides in the fact that it acts as a neurotransmitter rather than a hormone [89](#psc2954-bib-0089){ref-type="ref"}. NPY is one of the most abundant peptides found in the brain [90](#psc2954-bib-0090){ref-type="ref"}, and it is synthesised and released by neurons, which in the peripheral nervous system are mostly sympathetic neurons [89](#psc2954-bib-0089){ref-type="ref"}. NPY is associated with various biological responses, which include increased food intake, enhanced cognitive function associated with learning and memory and also reduction in anxiety [91](#psc2954-bib-0091){ref-type="ref"}. In addition to this, in peripheral blood vessels, NPY has been shown to induce vasoconstriction [92](#psc2954-bib-0092){ref-type="ref"}. Studies of NPY and its receptors suggest that it could be directly related to various pathological disorders such as obesity, depression and epilepsy [93](#psc2954-bib-0093){ref-type="ref"}.

Peptide Therapeutics {#psc2954-sec-0022}
====================

There are many peptide products on the market at present, and this are likely to increase because of their specificity, potency and low toxicity [94](#psc2954-bib-0094){ref-type="ref"}, [95](#psc2954-bib-0095){ref-type="ref"}. Table [1](#psc2954-tbl-0001){ref-type="table-wrap"} shows some of the leading peptide therapeutics. Not all of these peptide therapeutics self‐assemble or are formulated as solutions, but the table shows examples highlighting the importance of the use of peptides in drugs. The highest selling marketed diabetic drug Liraglutide incorporates a lipid chain to extent plasma circulation and ensures prolonged bioavailability [96](#psc2954-bib-0096){ref-type="ref"}, [97](#psc2954-bib-0097){ref-type="ref"}. Liraglutide is a GLP‐1 agonist drug that self‐assembles into an *α*‐helical structure, and it requires once a day administration [98](#psc2954-bib-0098){ref-type="ref"}. Lipid conjugation of a palmitoyl chain to a lysine residue at position 26 of liraglutide results in an extended half‐life (around 13--14 h) in the blood. This is due to the palmitoyl chain allowing non‐covalent binding to albumin, which delays proteolytic attack by DPP‐4 and also rapid renal clearance. Furthermore, the addition of the lipid chain could further prolong half‐life by sterically hindering the DPP‐4 enzyme from degradation [99](#psc2954-bib-0099){ref-type="ref"}.

Another peptide known to self‐assemble is the octapeptide Lanreotide. This compound is a synthetic analogue of the peptide hormone somatostatin, and it is used to treat acromegaly [100](#psc2954-bib-0100){ref-type="ref"} (a condition where the body produced too much growth hormone). In water, lanreotide self‐assembles into monodisperse liquid crystalline nanotubes. The nanotubes are made up of dimers that self‐assemble into a 2D crystal, which is held together by lateral chain interactions within antiparallel *ß*‐sheets [100](#psc2954-bib-0100){ref-type="ref"}, [101](#psc2954-bib-0101){ref-type="ref"}.

Daptomycin is a lipopeptide therapeutic agent that is used as an antibiotic to treat infections caused by Gram‐positive bacteria [102](#psc2954-bib-0102){ref-type="ref"}. This drug is particularly effective against infections that are antimicrobial resistant such as MRSA. The antimicrobial activity of daptomycin is calcium‐dependent. In the presence of a 1 : 1 ratio of calcium ions to daptomycin, self‐assembly into micelles has been observed. The mechanism of action involves the disruption of the negatively charged bacterial cell membrane, in the presence of cations (for antibiotic activity, this is calcium ions) [53](#psc2954-bib-0053){ref-type="ref"}.

A further example of how self‐assembly and bioactivity of peptide hormones are related involves self‐assembling amyloid structures formed by peptide hormones and neuropeptides, which are crucial messenger molecules responsible for the function of different cells and organs. Peptide hormones and neuropeptides form aggregates that pack into dense‐core vesicles (DCVs), which are used to temporararily store peptide messengers in secretory cells [103](#psc2954-bib-0103){ref-type="ref"}. When DCVs are triggered, they release the stored contents into the blood or extracellular space [104](#psc2954-bib-0104){ref-type="ref"}, which results in amyloid disassembly, in order for action [103](#psc2954-bib-0103){ref-type="ref"}. Therefore, for these types of peptides, reversibility of peptide aggregation is essential for their function.

As mentioned earlier, Table [1](#psc2954-tbl-0001){ref-type="table-wrap"} shows some examples of peptide agents that are currently on the market.

Therapeutic Applications of PYY Peptides {#psc2954-sec-0023}
========================================

A significant amount of research into the effects that PYY and PYY~(3--36)~ have on the body has been undertaken, predominately in the food/biological science fields [129](#psc2954-bib-0129){ref-type="ref"}, [130](#psc2954-bib-0130){ref-type="ref"}, [131](#psc2954-bib-0131){ref-type="ref"}. The application of PYY~(3--36)~ as an anti‐obesity drug is an extremely interesting topic of research; however, it is limited because of its short half‐life and lack of selectivity for the Y~2~‐receptor [85](#psc2954-bib-0085){ref-type="ref"}. As a result, there is an unmet need for a treatment, and because peptide hormones already exist, *in vivo* peptide‐based drugs are very favourable compared with synthetic molecules. This is due to them being less toxic, more selective and also more predictable in their *in vivo* behaviour [132](#psc2954-bib-0132){ref-type="ref"}. In contrast, however, the use of peptides and proteins as therapeutic agents has its drawbacks because of their rapid degradation, excretion, and poor water solubility. In addition to this, they may cause allergic reactions due to immune responses. However, this applies more to proteins than peptides as peptides are generally less immunogenic. One of the main reasons for the short half‐life of peptides is due to their rapid renal excretion, and this can be overcome by increasing the molecular weight (upper limited \>2000 gmol^−1^). A strategy to do this is to PEGylate the peptides. Covalently attaching PEG chains to the peptide improves enzymatic stability because of steric hindrance of proteolytic enzymes. This suppressed the immune response [132](#psc2954-bib-0132){ref-type="ref"}, [133](#psc2954-bib-0133){ref-type="ref"}, [134](#psc2954-bib-0134){ref-type="ref"}. PEGylation has been shown to induce vacuolisation (formation of vacuoles within/adjacent to cells), but current research has focused on limiting this effect by using different carriers or shortening chain lengths [135](#psc2954-bib-0135){ref-type="ref"}, [136](#psc2954-bib-0136){ref-type="ref"}, [137](#psc2954-bib-0137){ref-type="ref"}. In addition to extending half‐life, PEGylation exhibits many properties that are favourable in pharmaceutical applications such as high water solubility, low toxicity and immunogenicity and ready clearance from the body. An example to show the effectiveness of PEGylation on half‐life is the study by Lee *et al.*, where site‐specific mono‐PEGylation of GLP‐1 led to a 16‐fold increase in plasma half‐life time in rats [138](#psc2954-bib-0138){ref-type="ref"}.

As previously mentioned, the ability of PYY and PYY~3--36~ to reduce food intake makes this peptide promising for use in anti‐obesity or chronic eating disorder medications. A few studies have shown that even though PYY works as an appetite suppressant, it has some drawbacks that need to be overcome. A few studies that used high doses of PYY have reported taste aversion in animals and nausea in humans [139](#psc2954-bib-0139){ref-type="ref"}, [140](#psc2954-bib-0140){ref-type="ref"}. This was compounded by rapid dose administration. These side effects were combated by low doses at a steady and controlled infusion mainly through intravenous injections [141](#psc2954-bib-0141){ref-type="ref"}. The two main problems with the administration of PYY seem to be both its concentration and how it is given, with the optimum dose being obtained by intravenous administration [142](#psc2954-bib-0142){ref-type="ref"}. This is a detriment for the patient as they have to inject themselves, potentially daily, during the programme, and this can cause problems. Oral or nasal delivery gets over these issues, but with potential efficacy issues due to uptake [143](#psc2954-bib-0143){ref-type="ref"}, [144](#psc2954-bib-0144){ref-type="ref"}.

A paper in 2002 commented on the potential for acute peripheral administration of PYY~(3--36)~ to inhibit food intake. PYY~(3--36)~ was injected into fasted (for 24 h) rats\' hypothalamuses, and this led to a significant decrease in food intake, even at doses as low as 100 μg kg^−1^ [145](#psc2954-bib-0145){ref-type="ref"}. This effect was initially controversial with very few other researchers being able to repeat the result [146](#psc2954-bib-0146){ref-type="ref"}. A theory behind the controversy was proposed, this being that the mice used in the repeat tests were unaccustomed to the laboratory environment, which increased their stress levels. Stress inherently reduces baseline food intake so it makes any investigations in anorectic agents difficult to assess [146](#psc2954-bib-0146){ref-type="ref"}. Further research into the use of PYY~(3--36)~ in human studies has found that obese subjects show normal levels of sensitivity to the appetite‐reducing effects [147](#psc2954-bib-0147){ref-type="ref"}.

Summary and Conclusions {#psc2954-sec-0024}
=======================

Peptides have many advantages as therapeutic agents. This is due to them being multifunctional and having a diverse range of applications; from antimicrobial agents to triggering a cellular release of hormones. Table [1](#psc2954-tbl-0001){ref-type="table-wrap"} provides a list of examples of peptide drugs currently on the market.

Lipidation is a useful tool to reduce the degradation of a drug, or to extend half‐life, with some of these effects probably being the result of self‐assembly, although much more work is needed to investigate the possibly of many lipidated (and also non‐lipidated) peptide drugs. Lipidation also enhances interactions of peptides with cell membranes.

As discussed earlier with appropriate examples, lipopeptides and PAs have a lot of interesting applications including use in antimicrobial and antifungal treatments, as skin care product ingredients, in drug delivery systems including those for hormone diseases as highlighted herein and in material templating in tissue engineering.

Peptide hormone therapeutics are of great interest as components of 'pre‐built' drugs that the human body has already created and responds to. This significantly reduces the work needed to find a synthetic drug that responds to the active site. One drawback is that peptide hormones *in vivo* are stable for a specific time frame, before being removed. This may be a problem if the peptide hormone is of interest as a drug candidate, due to rapid clearance from the body. This is where lipidation may be beneficial as it can lead to a reduction in the drug clearance rate and proteolytic degradation. This offers great potential in the development of future therapeutics.

The peptide hormone PYY~3--36~ is released by the L cells of the gastrointestinal tract following food intake and has a high selectivity for the Y~2~ receptor. The Y~2~ receptor is associated with the regulation of food intake and gastric emptying. As a result of this, the use of PYY~3--36~ as a peptide hormone therapeutic to treat lifestyle conditions such as obesity and type 2 diabetes is a very promising area of research. As previously mentioned though, peptide hormones have short half‐lives and are rapidly cleared from the body, which means that their activity as therapeutic agents will be short lived, and lipidation and PEGylation are strategies to overcome this.

In summary, this review has covered applications of peptide‐based molecules, especially peptide amphiphiles and lipopeptides, with a particular focus on peptide hormones and their uses as drugs. We have highlighted the limited number of studies so far in which it has been suggested that self‐assembly may influence bioactivity. Much more research is required into this fascinating subject as novel peptide‐based molecules emerge as future therapeutic agents.
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